LeonaBio Inc LONA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
Trading Information
- Previous Close Price
- $4.34
- Day Range
- $4.50–4.84
- 52-Week Range
- $2.32–14.00
- Bid/Ask
- $4.36 / $4.83
- Shares Outstanding
- 9.42M
- Market Cap
- $39.57M
- Volume/Avg
- 1,654 / 197,417
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 19
- Website
- https://www.leonabio.com
Valuation
Metric | LONA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.22 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | LONA |
|---|---|
Quick Ratio | 6.53 |
Current Ratio | 7.01 |
Interest Coverage | — |
Quick Ratio
LONA
Profitability
Metric | LONA |
|---|---|
Return on Assets (Normalized) | −117.76% |
Return on Equity (Normalized) | −198.90% |
Return on Invested Capital (Normalized) | −194.31% |
Return on Assets
LONA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|TSYfm$N | LOCK|T?>& | $138B | |||
| Moderna Inc MRNA | LOCK|>JP>X? | LOCK|$q | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|R>s%?h | LOCK|tT#GH | $93B | |||
| argenx SE ADR ARGX | LOCK|^!!hMj | LOCK|s? | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|@Y$!?V | LOCK|ywP | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|G%wTWSM | LOCK|d$>h | $30B | |||
| Incyte Corp INCY | LOCK|#!bQ?w# | LOCK|&n | $24B | |||
| BioNTech SE ADR BNTX | LOCK|%!zgt!p | LOCK|!G | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|QN%t?b | LOCK|f^#BP | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|>KX?@?p | LOCK|bLM | $15B |
United States